Zyversa Therapeutics Inc
NASDAQ:ZVSA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Z
|
Zyversa Therapeutics Inc
NASDAQ:ZVSA
|
US |
|
N
|
NXT-ID Inc
LSE:0KA8
|
US |
|
S
|
Sprix Ltd
TSE:7030
|
JP |
|
Sunjin Co Ltd
KRX:136490
|
KR |
|
Banan Real Estate Company SJSC
SAU:9519
|
SA |
|
Sundrug Co Ltd
TSE:9989
|
JP |
|
JTL Industries Ltd
NSE:JTLIND
|
IN |
|
Chengdu Qinchuan IoT Technology Co Ltd
SSE:688528
|
CN |
|
Companhia Brasileira de Aluminio
BOVESPA:CBAV3
|
BR |
|
R
|
Ram Ratna Wires Ltd
NSE:RAMRAT
|
IN |
|
InnoCare Pharma Ltd
HKEX:9969
|
CN |
|
Walaa Cooperative Insurance Company SJSC
SAU:8060
|
SA |
Income Statement
Earnings Waterfall
Zyversa Therapeutics Inc
Income Statement
Zyversa Therapeutics Inc
| Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||
| Interest Expense |
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||||
| Operating Expenses |
(8)
|
(9)
|
(9)
|
(10)
|
(14)
|
(15)
|
(18)
|
(18)
|
(14)
|
(106)
|
(22)
|
(22)
|
(9)
|
(8)
|
|
| Selling, General & Administrative |
(6)
|
(7)
|
(6)
|
(6)
|
(8)
|
(9)
|
(12)
|
(13)
|
(11)
|
(10)
|
(8)
|
(8)
|
(7)
|
(7)
|
|
| Research & Development |
(2)
|
(3)
|
(3)
|
(5)
|
(6)
|
(6)
|
(6)
|
(5)
|
(3)
|
(3)
|
(2)
|
(2)
|
(2)
|
(2)
|
|
| Depreciation & Amortization |
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(93)
|
(12)
|
(12)
|
0
|
0
|
|
| Operating Income |
(8)
N/A
|
(9)
-15%
|
(9)
0%
|
(10)
-17%
|
(14)
-33%
|
(15)
-9%
|
(18)
-22%
|
(18)
+3%
|
(14)
+19%
|
(106)
-635%
|
(22)
+79%
|
(22)
+3%
|
(9)
+58%
|
(8)
+7%
|
|
| Pre-Tax Income | |||||||||||||||
| Interest Income Expense |
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
(81)
|
(81)
|
(93)
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(8)
N/A
|
(10)
-20%
|
(10)
+1%
|
(11)
-19%
|
(15)
-30%
|
(16)
-6%
|
(100)
-537%
|
(99)
+1%
|
(108)
-9%
|
(106)
+2%
|
(22)
+79%
|
(22)
+2%
|
(9)
+57%
|
(9)
+6%
|
|
| Net Income | |||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
1
|
2
|
10
|
10
|
9
|
8
|
1
|
1
|
(0)
|
0
|
|
| Income from Continuing Operations |
(8)
|
(10)
|
(10)
|
(11)
|
(14)
|
(14)
|
(90)
|
(90)
|
(98)
|
(98)
|
(22)
|
(21)
|
(9)
|
(9)
|
|
| Net Income (Common) |
(8)
N/A
|
(10)
-20%
|
(10)
-2%
|
(21)
-116%
|
(24)
-13%
|
(24)
+1%
|
(108)
-351%
|
(98)
+10%
|
(106)
-9%
|
(106)
+1%
|
(22)
+79%
|
(21)
+2%
|
(9)
+56%
|
(9)
+6%
|
|
| EPS (Diluted) |
-307.38
N/A
|
-368.53
-20%
|
-377.67
-2%
|
-814.84
-116%
|
-917.81
-13%
|
-917
+0%
|
-2 118.18
-131%
|
-1 102.65
+48%
|
-1 089.7
+1%
|
-169.22
+84%
|
-26.18
+85%
|
-21.58
+18%
|
-8.48
+61%
|
-2.84
+67%
|
|